Eligible participants were women aged 42 years or younger with stage I–III hormone receptor–positive breast cancer who had completed between 18 and 30 months of adjuvant endocrine therapy and expressed the desire to pause treatment to pursue pregnancy. This evidence concerns the gene NR4A1 and breast cancer.